Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2020-03-05 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-03-05 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-27 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-26 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 26, 2020, by Madrigal Pharmaceuticals, Inc. It announces the issuance of a press release reporting the company's financial results for the fourth fiscal quarter and fiscal year ended December 31, 2019. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as Exhibit 99.1. The length of the document is 3668 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2020-02-26 English
10-K
Annual Report FY 2019
2020-02-26 English
SC 13G/A
Major Shareholding Notification
2020-02-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.